# Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

> **NCT07116967** · PHASE3 · RECRUITING · sponsor: **Bristol-Myers Squibb** · enrollment: 3040 (estimated)

## Conditions studied

- Plaque Psoriasis

## Interventions

- **DRUG:** Deucravacitinib
- **DRUG:** Ustekinumab

## Key facts

- **NCT ID:** NCT07116967
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-22
- **Primary completion:** 2031-01-16
- **Final completion:** 2031-01-16
- **Target enrollment:** 3040 (ESTIMATED)
- **Last updated:** 2026-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07116967

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07116967, "Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)". Retrieved via AI Analytics 2026-08-01 from https://api.ai-analytics.org/clinical/NCT07116967. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*